Neuroscience and neurodegeneration
6 European H2020 organizations list this as part of their work — 3 as their primary capability.
Most active in this area
- STICHTING AMSTERDAM UMC
Major Dutch academic medical center leading European research in cancer biomarkers, neurodegeneration, precision medicine, and advanced clinical imaging.
“Sustained work across EuroPOND (neurological disease progression), PANA (Alzheimer's nanodiagnostics), INDUCT (dementia technology), MINDMAP (mental wellbeing), and CP-RehOP (cerebral palsy rehabilitation).”
PrimaryNL144 projects - VIB VZW
Belgium's leading life sciences research institute, spanning immunology, neuroscience, plant biology, and structural biology with strong EU project leadership.
“Research on synaptic maintenance, protein aggregation in neurodegeneration, Alzheimer's disease mechanisms, and neural circuit function (projects: RobustSynapses, HEALTHYSYNAPSES, MANGO, AD-gut, AD-VIP, SorCSbalance).”
PrimaryBE126 projects - ASTRAZENECA AB
Global pharma company contributing drug safety data, clinical biomarkers, and AI-driven discovery to 58 H2020 health research consortia from Sweden.
“Participated in SyDAD (synaptic dysfunction in Alzheimer's), PHAGO (TREM2/neuroinflammation), MOPEAD (Alzheimer's patient engagement), and NeuroDeRisk.”
SE58 projects - F. HOFFMANN-LA ROCHE AG
Global pharma giant contributing drug safety data, biomarker expertise, and diagnostics capabilities to 45 H2020 health consortia across neuroscience, toxicology, and clinical trials.
“Active across AIMS-2-TRIALS (autism), PHAGO and ROADMAP (Alzheimer's), COSYN (psychiatric comorbidity), PRISM (psychiatric stratification), NEURONET, and IDEA-FAST.”
PrimaryCH45 projects - INSTITUTO DE MEDICINA MOLECULAR JOAO LOBO ANTUNES
Lisbon-based biomedical research institute strong in T cell immunology, targeted cancer therapeutics, and 3D tissue models, with 81% project coordination rate.
“SynapticMitochondria on mitochondrial quality control at synapses, FAIR-PARK-II on iron chelation for Parkinson's disease, and GliaInnateSensing on glial cell function.”
SMEPT32 projects - LATVIJAS ORGANISKAS SINTEZES INSTITUTS
Latvia's premier medicinal chemistry and drug discovery institute, combining organic synthesis with structural biology for pharmaceutical R&D across Europe.
“FAT4BRAIN (fatty acid metabolism in neurological function, as coordinator), InterTAU (tau protein in Alzheimer's), and Oligomers-MAS-NMR (amyloid oligomers).”
LV18 projects